Dr. William Joseph Reschly, MD

Dr. Reschly practices at Ear, Nose & Throat Associates in Clearwater, Florida.

Dr. Reschly's NPI, 1386063311, was assigned on April 7, 2014. Dr. Reschly graduated from Frederick P. Whiddon College of Medicine in 2014. Dr. Reschly holds Florida license ME139498.

Dr. Reschly's primary practice is Ear, Nose & Throat Associates, at 3190 N Mcmullen Booth Rd Suite 100 Suite 100, Clearwater, FL 33761-2013. The practice phone is (727) 791-1368.

Dr. Reschly's primary practice is Ear, Nose & Throat Associates in Clearwater, Florida. Dr. Reschly is also affiliated with Morton Plant Hospital. The medical group on file is Ear, Nose & Throat Associates. Dmand AI also links Dr. Reschly to 4 more hospitals and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Reschly practices, 7 sites in all. Vendor and product names are available with a free account.

Otolaryngology is Dr. Reschly's primary specialty in the NPI Registry, under taxonomy code 207Y00000X. Dr. Reschly is board certified in otolaryngology by the American Board of Otolaryngology - Head and Neck Surgery. Dr. Reschly is licensed in Florida.

Dmand AI lists chronic nasal allergies, chronic sinusitis, ear eustachian tube disorders, endoscopic sinus surgery, hearing loss and impairment, swimmer's ear, thyroid surgery and tinnitus among the conditions Dr. Reschly treats.

CMS data shows 1,565 Medicare services from Dr. Reschly across 17 procedure codes in 2024, for 543 Medicare patients. Medicare paid $167,679 for them.

CMS counts 543 Medicare patients who saw Dr. Reschly in 2024. The largest group is 75 to 84, with 246 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.76, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Reschly's median patient age at 70, with 46% women.

In 2024, Dr. Reschly wrote 1,654 Medicare Part D claims for 568 patients. 98% of them were for generic drugs. CMS names the drug for 1,519 of them, across 30 drugs with 11 or more claims each, at $24,178 in total drug cost. In 2023, CMS named 1,319 claims across 24 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Reschly for performance year 2024, reported individually. Dr. Reschly accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 15 procedures of melanoma (skin cancer) excision by Dr. Reschly, more than 70% of the clinicians it reports for that procedure.

Spinal fusion: 1 to 10 procedures (CMS shows small counts as a range)

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 5 papers to Dr. Reschly, published from 2018 to 2025. The most frequent topics are Free Tissue Flaps and Plastic Surgery Procedures. Dr. Reschly's most frequent co-authors are Peter T. Dziegielewski, MD, Deepa Danan, MD and William M. Mendenhall, MD.

CMS Open Payments shows 39 general payments to Dr. Reschly from 12 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 55% of the total. Stryker Corporation paid the most, $1,954.

Dr. Reschly graduated from Frederick P. Whiddon College of Medicine in 2014.

Dr. Reschly is in network with 19 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.